Every 10-Q that Spyre Therapeutics, Inc. (SYRE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SYRE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SYRE filings page.
Spyre Therapeutics, Inc. reported a net loss of $36.2 million for the quarter ended June 30, 2026 and $105.2 million for the first half of 2026, reflecting heavy investment in its immunology pipeline. Research and development expenses rose to $65.5 million in the quarter and $125.9 million year-to-date, driven by manufacturing and clinical trial spending in IBD and rheumatic disease programs.
Results include a $40.0 million quarterly gain ($70.0 million year-to-date) from milestone payments on the 2023 sale of pegzilarginase rights, partly offset by a $34.9 million increase in the contingent value right liability tied to those legacy assets. Liquidity strengthened through a $435.2 million April 2026 underwritten equity offering and $9.7 million of at-the-market sales; cash, cash equivalents and marketable securities totaled $1.1 billion as of June 30, 2026, which management expects to fund operations for at least one year. The company remains a clinical-stage biotech with no product revenue and states it will need additional financing to complete development and commercialization.
Spyre Therapeutics, Inc. reported a net loss of $69.0 million for the quarter ended March 31, 2026, wider than $44.8 million a year earlier, driven mainly by higher research and development spending of $60.4 million and increased general and administrative expenses of $15.2 million.
The company recorded a $30.0 million gain from a milestone on the prior sale of pegzilarginase rights to Immedica, while its contingent value right (CVR) liability rose to $56.9 million. Cash, cash equivalents and marketable securities totaled $741.5 million as of March 31, 2026, before an additional $435.3 million in net proceeds from an April 2026 equity offering.
Spyre Therapeutics, Inc. (SYRE) reported a smaller quarterly loss as non-operating gains offset steady R&D spend. For the three months ended September 30, 2025, net loss was $11.2 million versus $69.0 million a year ago. Operating expenses were $56.9 million, including $45.2 million in research and development and $11.6 million in general and administrative costs. Other income totaled $45.7 million, aided by the decrease in the CVR liability recorded in other income (expense).
Liquidity remained strong with $486.2 million in cash, cash equivalents and marketable securities as of September 30, 2025. The CVR liability fell to $14.25 million from $61.7 million at year‑end. Cash used in operating activities for the nine months was $124.7 million. Stockholders’ equity was $455.1 million.
Subsequent to quarter end, on October 15, 2025, the company closed an underwritten offering of common stock for net proceeds of $296.5 million. Shares of common stock outstanding were 60,471,793 as of September 30, 2025, and 77,592,130 as of October 29, 2025.